Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2017 02:15 ET | Source: Novartis Pharma AG

Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis

New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before treatment...
March 18, 2017 09:45 ET | Source: Novartis Pharma AG

New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes

New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced...
March 13, 2017 15:07 ET | Source: Novartis Pharma AG

Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor

Approved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] At...
March 13, 2017 02:15 ET | Source: Novartis Pharma AG

Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)

Three winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines. Winning ideas...
March 06, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause

New analysis shows 94% of patients on Cosentyx® regained PASI 75, with up to 80% of patients regaining PASI 90 to 100 after only 16 weeks of retreatment[1] Cosentyx has shown superior and...
March 06, 2017 01:10 ET | Source: Novartis Pharma AG

New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine

Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*Comprehensive development program show potential of...
February 28, 2017 07:44 ET | Source: Novartis Pharma AG

Novartis Aktionäre genehmigen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats

Aktionäre genehmigen für 2016 die 20. Dividendenerhöhung in Folge auf CHF 2,75 pro Aktie (+2%) - dies entspricht einer Rendite von 3,5% und einer Ausschüttungsquote von circa 69% des Free Cashflow ...
February 28, 2017 07:44 ET | Source: Novartis Pharma AG

Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting

Shareholders approve 20th consecutive dividend increase to CHF 2.75 (+2%) per share for 2016; representing a 3.5% yield and approximately 69% payout of free cash flow Dr. Joerg Reinhardt...
February 28, 2017 07:44 ET | Source: Novartis Pharma AG

Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration lors de l'Assemblée générale annuelle

Les actionnaires approuvent la 20e hausse consécutive du dividende, à CHF 2,75 (+2 %) par action au titre de l'exercice 2016. Cela représente un rendement de 3,5 % et une distribution du free...
February 24, 2017 07:07 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patients

If approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation CHMP opinion based on positive data from pivotal study of patients...